UNSPSC 51343819: Nevirapine and lamivudine/zidovudine

This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.

UNSPSC 51343819, Nevirapine and lamivudine/zidovudine, is a Commodity code that shows minimal direct alignment with recent state and local procurement activity. The code nominally identifies specific antiretroviral pharmaceutical ingredients used in HIV treatment, but the recent opportunities tagged to this code do not reflect procurement of these drugs or related pharmaceutical inventory; instead, the opportunities span emergency medical services software, long-term care pharmacy services, drug standards for forensic laboratories, naloxone distribution, and opioid-settlement grant administration—none of which involve nevirapine or lamivudine/zidovudine procurement. The mismatch suggests either broad-spectrum tagging in procurement systems or administrative classification drift that separates the code's nominal scope from actual buying patterns.

The source identifies no state or local contract opportunities actively soliciting nevirapine or lamivudine/zidovudine products, quantities, or delivery arrangements. Geographic distribution, issuing-body concentration, and representative current opportunities within the code's intended scope cannot be characterized from the available records.